RHY 8.57% 7.6¢ rhythm biosciences limited

Sept '21 Deloitte's review of the National Bowel Cancer Screening Program, page-3

  1. 280 Posts.
    lightbulb Created with Sketch. 95
    @borano


    Review of Phase Four of the National Bowel Cancer Screening Program:

    "In any decision to transition to a new test type, it is important that the test is approved by the
    Therapeutic Goods Administration (as per the guidance in the NBCSP Quality Framework) and a
    cost-effectiveness analysis is performed using reliable estimates of test sensitivity and specificity,
    as compared with the current iFOBT."
 
watchlist Created with Sketch. Add RHY (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.